Who is sponsoring NCT02909946?

NCT02909946 is sponsored by University of Michigan.

What drugs are being tested in NCT02909946?

Interventions in NCT02909946: Multi-modal Infection Control Program.

What condition does NCT02909946 study?

NCT02909946 studies Multi-antibiotic Resistance.

Is NCT02909946 still recruiting?

NCT02909946 is currently completed. Last updated 19 September 2018.

Last reviewed 2018-09-19 · How we verify

NCT02909946

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pathway From Functional Disability to Antimicrobial Resistance in Nursing Home Residents

Completed NA Last updated 19 September 2018

What this trial tests

NA trial testing Multi-modal Infection Control Program in Multi-antibiotic Resistance in 246 participants. Completed in 29 August 2018.

Timeline

15 September 2016

Primary endpoint
15 August 2018

29 August 2018

Quick facts

Lead sponsor	University of Michigan
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	246
Start date	15 September 2016
Primary completion	15 August 2018
Estimated completion	29 August 2018
Sites	1 location across United States

Drugs / interventions tested

Multi-modal Infection Control Program

Conditions studied

Multi-antibiotic Resistance — all drugs for Multi-antibiotic Resistance →

Sponsor

University of Michigan

Who can join

18 and older, any sex, with Multi-antibiotic Resistance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multidrug-resistant organisms (MDROs) are endemic in nursing homes (NHs) with prevalence rates surpassing those in hospitals. The aim of the study is to design and evaluate the effectiveness of a multi-component intervention to reduce new acquisition of MDROs in NH residents. The intervention will incorporate resident-level, environmental, and caregiver based strategies. Using a cluster-randomized study design, three NHs will be randomized to the intervention group and three to the control group. Control NHs will be allowed to continue standard infection prevention practices. Nursing homes will serve as the unit of allocation. Analyses will be performed both at the resident and the cluster level. The primary outcomes of the study are reduction in MDRO prevalence, and reduction in new MDRO acquisition .

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effectiveness of a Multicomponent Intervention to Reduce Multidrug-Resistant Organisms in Nursing Homes: A Cluster Randomized Clinical Trial.
Mody L, Gontjes KJ, Cassone M, Gibson KE, et al · · 2021 · cited 19× · PMID 34269807 · DOI 10.1001/jamanetworkopen.2021.16555

Verify or expand the search:

Other recruiting trials for Multi-antibiotic Resistance

Currently open trials in the same condition.

NCT04759001 — FMT for the Decolonization of Carbapenem-resistant Enterobacteriaceae · Phase 1, PHASE2 · recruiting
NCT06148480 — Perinatal Transmission of MDR Bacteria · recruiting

Other University of Michigan trials

Trials by the same sponsor.

NCT07536919 — Integrating Care for Hypertension-Diabetes MULTImorbidity in Guatemala Through HEARTS Implementation · NA · not yet recruiting
NCT05509842 — Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson's Disease (PD) · NA · not yet recruiting
NCT06311188 — Exploring PTSD Symptoms, Barriers and Facilitators to Mindfulness · NA · not yet recruiting
NCT07471646 — Effects of Ramadan Fasting With Exercise on Cardiometabolic Health · NA · not yet recruiting
NCT06671925 — A Community Health Worker-Led Program for Chronic Pain and Loneliness in Older Adults · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02909946 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Michigan
Last refreshed: 19 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02909946.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing